The Role of Ocrelizumab in Multiple Sclerosis Treatment

[1]  M. Filippi,et al.  Anti-CD20 therapies for multiple sclerosis: current status and future perspectives , 2021, Journal of Neurology.

[2]  Jeffrey A. Cohen,et al.  Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis , 2021, CNS Drugs.

[3]  A. Cross,et al.  Anti-CD20 B Cell Treatment for Relapsing Multiple Sclerosis , 2021, Frontiers in Neurology.

[4]  A. Sempere,et al.  Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population , 2020, Annals of clinical and translational neurology.

[5]  H. Hartung,et al.  Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis , 2020, Multiple Sclerosis and Related Disorders.

[6]  Farirai P Nzvere,et al.  Role of Smoking in the Pathogenesis of Multiple Sclerosis: A Review Article , 2020, Cureus.

[7]  O. Ciccarelli,et al.  Ocrelizumab for Treating Patients with Primary Progressive Multiple Sclerosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal , 2020, PharmacoEconomics.

[8]  P. Sørensen,et al.  Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis , 2020, CNS Drugs.

[9]  B. Hemmer,et al.  CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date , 2019, Expert opinion on biological therapy.

[10]  Howard Thom,et al.  Systematic review and network meta-analysis comparing ocrelizumab with other treatments for relapsing multiple sclerosis. , 2019, Multiple sclerosis and related disorders.

[11]  R. Milo.  Therapies for multiple sclerosis targeting B cells , 2019, Croatian medical journal.

[12]  T. Holmøy,et al.  B cell depletion in the treatment of multiple sclerosis , 2019, Expert opinion on biological therapy.

[13]  J. de Seze,et al.  Ocrelizumab for the treatment of multiple sclerosis , 2018, Expert review of neurotherapeutics.

[14]  R. Jacobs,et al.  Ocrelizumab Depletes CD20+ T Cells in Multiple Sclerosis Patients , 2018, Cells.

[15]  Yahiya Y. Syed.  Ocrelizumab: A Review in Multiple Sclerosis , 2018, CNS Drugs.

[16]  X. Montalban,et al.  Ocrelizumab: a new milestone in multiple sclerosis therapy , 2018, Therapeutic advances in neurological disorders.

[17]  D. Younger,et al.  Epidemiology of Multiple Sclerosis. , 2016, Neurologic clinics.

[18]  J. Correale,et al.  Progressive multiple sclerosis: from pathogenic mechanisms to treatment. , 2016, Brain : a journal of neurology.

[19]  H. Hartung,et al.  Ocrelizumab for the treatment of relapsing-remitting multiple sclerosis , 2016, Expert review of neurotherapeutics.